The Herbal Reflux Trial Worth Reading Carefully, Not Copying at Home

Sat, 05 Sep 2026 08:45:00 +0700

A Chinese herbal reflux trial can be interesting precisely because it was so carefully defined.

That’s the part people may miss with the 2026 Xiangsu Hewei Granules study. A multicenter, randomized, double-blind phase III trial reported much higher 8-week symptom-response rates for heartburn and acid regurgitation in a selected non-erosive reflux disease group than in the placebo/low-dose control group (PubMed; ScienceDirect).

But the careful definition is also the warning label. This was not “anyone with heartburn.” It was adults 18-65 with confirmed non-erosive GERD, a GerdQ score of at least 8, negative H. pylori status, low anxiety/depression scores, and a specific traditional Chinese medicine pattern described as liver-stomach stagnation heat syndrome (PubMed).

So the takeaway isn’t “try this for reflux.” It is much narrower (and more useful): a promising herbal-medicine trial still has to be read against diagnosis, product identity, standard GERD care, red flags, interactions, and supplement-quality rules.

GERD on Alternative Medicine Zone

The Herbal Reflux Trial Worth Reading Carefully, Not Copying at Home